Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Ovarian Neoplasms 11Prostatic Neoplasms 7Fallopian Tube Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1SCLC,Extensive Stage 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Carcinosarcoma 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Lung Neoplasms 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 52Carboplatin 49pembrolizumab 45Magnetic Resonance Spectroscopy 44Pemetrexed 39Cisplatin 34Paclitaxel 24durvalumab 23osimertinib 20Nivolumab 19Gemcitabine 19Radiosurgery 17Docetaxel 17atezolizumab 15Taxes 12Radiotherapy 12Immunoglobulin G 12Disulfides 12Biopsy 12130-nm albumin-bound paclitaxel 12Etoposide 11Educational Status 11Radiation 10Drug Therapy 10Blood Specimen Collection 10Platinum 9Early Intervention, Educational 9Cetuximab 9Methods 8Bevacizumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × niraparib × 90 days × Clear all
NCT04701307 2026-04-22

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
48 enrolled
EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡